Bladder cancer is a highly prevalent disease, with an estimated 77,000 new cases and 14,000 deaths in 2016. The bladder cancer SPORE, initiated in 2001, is developing new cancer interventions through molecular-based translational research. Complementarity translational projects from this research team are expanding our understanding of the genesis, progression, and metastasis of bladder cancer and developing novel strategies for the prevention and treatment of this disease. The projects are elucidating the molecular mechanisms of early clinically occult phases of bladder carcinogenesis and the molecular subtypes of invasive disease. The new molecular insights are leading to improvements in prognostication and prediction of treatment response. Novel therapies developed by the bladder SPORE promise to improve the treatment outcome of patients with this disease. This SPORE is also advancing its translational research successes towards clinical utility through patenting and licensing.
The SPORE in bladder cancer has become a catalyst for collaborative translational research. This is exemplified by this SPORE’s leading role in establishing and supporting the International Bladder Cancer Marker Network, which collaborated in the development of tissue arrays to evaluate the prognostic and predictive utility of multiple markers. This SPORE organized a number of meetings with leaders in the field to educate the urologic oncology community and to foster collaborative efforts to solve the problem of bladder cancer.
David J. McConkey, Ph.D.
Professor, Urology Research
The University of Texas
MD Anderson Cancer Center
1515 Holcombe Blvd, Unit 1373
Houston, TX 77030
For more information on this specific SPORE’s institution, please visit: